SUGENTECH INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,380 KRW | -1.28% |
|
-5.94% | -30.58% |
| 2023 | Tranche Update on Sugentech Inc.'s Equity Buyback Plan announced on March 29, 2023. | CI |
| 2023 | Tranche Update on Sugentech Inc.'s Equity Buyback Plan announced on March 29, 2023. | CI |
| Sales 2022 | 101B 73.62M | Sales 2023 | 7.13B 5.18M | Capitalization | 118B 85.98M |
|---|---|---|---|---|---|
| Net income 2022 | 26.72B 19.4M | Net income 2023 | -17.24B -12.51M | EV / Sales 2022 | 0.71 x |
| Net cash position 2022 | 93.57B 67.93M | Net cash position 2023 | 51.51B 37.4M | EV / Sales 2023 | 9.38 x |
| P/E ratio 2022 |
6.73
x | P/E ratio 2023 |
-13.6
x | Employees | 137 |
| Yield 2022 |
1.48% | Yield 2023 |
-
| Free-Float | 85.2% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.28% | ||
| 1 week | -5.94% | ||
| Current month | -15.67% | ||
| 1 month | -27.79% | ||
| 3 months | -19.10% | ||
| 6 months | -14.47% | ||
| Current year | -30.58% |
1 week
5 310.00
5 790.00
1 month
5 310.007 080.00
Current year
5 310.009 120.00
1 year
5 310.0011 200.00
3 years
5 310.0036 400.00
5 years
4 510.0065 800.00
10 years
4 510.0065 800.00
| Managers | Title | Age | Since |
|---|---|---|---|
Seong-Bum Yoo
FOU | Founder | 57 | 11-12-08 |
Eun-Kyung Kim
FOU | Founder | 49 | 11-12-08 |
Mi-Jin Sohn
FOU | Founder | 59 | 11-12-08 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mi-Jin Sohn
FOU | Founder | 59 | 11-12-08 |
Jong-Yoon Park
DFI | Director of Finance/CFO | 46 | - |
Seong-Bum Yoo
FOU | Founder | 57 | 11-12-08 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 5,380 | -1.28% | 79 091 |
| 24-04-25 | 5,450 | -3.20% | 101,283 |
| 24-04-24 | 5,630 | 0.00% | 55,517 |
| 24-04-23 | 5,630 | -0.35% | 55,214 |
| 24-04-22 | 5,650 | -0.70% | 68,057 |
End-of-day quote Korea S.E., April 25, 2024
More quotes
Sugentech Incorporate is a Korea-based company mainly engaged in the production and sale of in-vitro diagnostic test reagents. The Company is involved in the manufacturing and sale of in vitro diagnostic test reagents, point-of-care testing (POCT) products, folic acid products under the name of SOLGAR, as well as molecular diagnostic reagents. The in vitro diagnostic test reagents are for personal use and are sold under the name SUREARLY. The POCT products are for professional use and are sold under the name INCLIX. In addition, the Company is engaged in therapeutic drug monitoring, as well as drug analysis method development. The Company distributes its products within the domestic market and to overseas markets, including Indonesia.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -30.58% | 60.59M | |
| +0.89% | 12.59B | |
| -10.29% | 7.42B | |
| +1.78% | 5.35B | |
| -1.16% | 4.51B | |
| +5.81% | 4.47B | |
| -50.63% | 3.21B | |
| +12.21% | 2.71B | |
| -16.13% | 1.96B | |
| -11.50% | 1.73B |
- Stock Market
- Equities
- A253840 Stock
